Dec 18,2018

Palo Alto Health Sciences Obtains FDA-Clearance for Freespira in Treating Post-Traumatic Stress Disorder

Palo Alto Health Sciences, Inc. (PAHS) announced today that its flagship digital therapeutic, Freespira®, has been cleared by the FDA as a treatment option for patients diagnosed with post-traumatic stress disorder (PTSD). Freespira is a 4-week, drug-free treatment for PTSD, panic disorder, panic attacks, and other panic symptoms. Patients complete two 17-minute in-home sessions every day for 4 weeks under the supervision by a licensed healthcare provider.

REGULATORY FDA
View Analyst & Ambassador Comments
Go to original news
Dec 13,2017

AmalgamRX to launch stress reduction app for patients with psoriasis, psoriatic arthritis

Digital therapy platform AmalgamRX has just announced the upcoming launch of its new app, Beyond, which aims to help patients living with psoriasis and psoriatic arthritis providing them resources to manage stress. Based on cognitive behavioral strategies, the app is specifically designed to help patients with the stress that can cause flare-ups. Through activities and resources, it gives user techniques for reducing their stress and increasing their optimism level.

PRODUCT

#mobile app

#coaching

#cbt

View Analyst & Ambassador Comments
Go to original news
Feb 16,2017

Five digital health trends investors are watching in 2017

Skip Fleshman is a partner at Asset Management Ventures who has invested in companies such as Proteus Digital Health, WellDoc, HealthTap, Evidation Health, Reify Health, Lark and Welkin. He shares his insights and opnions ont he digital health trends including digital therapeutics. He pointed interesting companies in this sector target diabetes prevention (Omada Health), Type 2 diabetes (WellDoc), mental health (Pear Therapeutics) and respiratory illness (Propeller Health).

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Jun 08,2017

This adorable chatbot wants to talk about your mental health

Woebot, one of the first chatbots of its kind, is powered by artificial intelligence not to tackle your deepest problems, but to improve your mood, and even alleviate symptoms of depression. The chatbot also represents the risky yet essential innovation happening at the intersection of mental health care and technology.

PRODUCT

#chatbot

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 24,2016

The Largest And Longest Study Of Patients With Schizophrenia Interacting With Digital Therapeutics Results Released

Pear Therapeutics (PEAR), the creator of prescription digital therapies called eFormulations, announced today results from a real-world implementation study examining a research version of THRIVE, PEAR’s digital therapy for treating patients with Serious Mental Illness including schizophrenia, schizoaffective disorder, and bipolar disorder. The study evaluated 342 participants between 18-60 years of age, who had been diagnosed with a psychotic disorder and were discharged from a psychiatric hospitalization within 60 days. Seventy-four percent (73.6%) of patients were successfully able to use the digital therapy 3-6 months after discharge, and on average, participants used the digital therapy for 82% of the weeks they had a mobile phone.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 05,2014

PARTNERSHIP WITH ANYCARE GMBH | SILVERCLOUD HEALTH

SilverCloud Health, a global provider of behavioural and mental wellness online solutions, announced further expansion into the European healthcare market through a strategic partnership with German healthcare provider AnyCare GmbH. SilverCloud Health will work with AnyCare to translate its online platform and therapeutic programmes for stress, anxiety, and depression into German.

COLLABORATION PARTNERSHIP

#product & service

#cbt

View Analyst & Ambassador Comments
Go to original news
Jan 23,2023

Medi-Cal Members Can Now Get Innovative Digital Programs to Prevent, Treat, Reverse Chronic Conditions

Blue Shield of California Promise Health Plan is now offering its Medi-Cal members Wellvolution, a digitally based lifestyle medicine and mental health support program that can be personalized to address individual health needs and preferences. Wellvolution programs that Medi-Cal members can access includes Diabetes Prevention program of 12-weeks for eligible members, chronic-condition reversal for diabetes and obesity, mindfullness and mental health services as well as the tobacco cessation digital therapies.

PRODUCT

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 30,2023

Study backs digital diabetes program from Vida Health

San Francisco-based Vida Health published an article in JMIR Formative Research. Results from 1,128 participants demonstrated dramatic improvements in glycemic control. It also highlighted an important relationship between the improved management of depression and diabetes. Participants enrolled in Vida’s interactive digital health diabetes management program. The company designed it to enable members to manage both physical and mental health.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Dec 08,2022

Vida Health’s Spanish-Language Virtual Diabetes Solution Achieves Meaningful Clinical Outcomes

New research published in JMIR Formative Research shows clinically significant Hemoglobin A1C (HbA1C) reduction for a diabetic population who used Vida Health’s Spanish solution. These clinical outcomes reinforce the importance of providing accessible care that’s adapted to fit the needs of diverse populations.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jan 01,2022

Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-only Digital Therapeutic for Acute Myeloid Leukemia

Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for BNT200. BNT200 is a first-of-its-kind prescription-only digital therapeutic to treat anxiety and depressive symptoms in adults with acute myeloid leukemia (AML) who are hospitalized for a regimen of high-intensity induction chemotherapy.

REGULATORY FDA

#pdt

View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH